2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
December 6th 2017
Hope S. Rugo, MD, discusses a variety of agents for the treatment of patients with ER-positive breast cancer, such as mTOR inhibitors, PI3K inhibitors, and CDK4/6 inhibitors, in addition to novel targeted therapies being investigated in TNBC.
December 4th 2017
Brady L. Stein, MD, discusses the differences between the types of MPNs, the NCCN guideline changes, and the important role of JAK inhibitors.
December 1st 2017
Sunita D. Nasta, MD, compares the biology of peripheral and cutaneous T-cell lymphomas and offered advice on the optimal therapeutic approaches for either disease with novel agents.
November 30th 2017
Alexander E. Perl, MD, discusses the future of FLT3 inhibitors, current obstacles with treating patients with acute myeloid leukemia, and what pivotal trial results the community can expect to hear in the coming months.
November 22nd 2017
Tanya B. Dorff, MD, discusses several important components regarding metastatic castration-resistant prostate cancer treatment, including the addition of novel drugs, optimal therapeutic sequences, and the identification of predictive biomarkers.
November 21st 2017
Scott Paulson, MD, discusses developments with NETs and liver cancer.
November 15th 2017
Przemyslaw W. Twardowski, MD, discusses a variety of factors to consider when treating patients with prostate cancer.
November 14th 2017
Guru P. Sonpavde, MD, discusses degarelix, androgen-deprivation therapy, and ongoing trials with immunotherapy that are crucial to advancing the treatment of patients with prostate cancer.
November 14th 2017
Leo I. Gordon, MD, discusses promising advances and lingering challenges with novel treatments for patients with hematologic malignancies.
November 3rd 2017
Edward A. Stadtmauer, MD, sheds light on the future of chimeric antigen receptor T-cell therapy, systemic therapeutic advances in the field of acute myeloid leukemia, and remaining challenges in the multiple myeloma paradigm.
November 1st 2017
Laura J. van’t Veer, PhD, discusses determining more accurate methods of treatment for patients with early- and late-state breast cancer based on advances in genetic testing, specifically the 70-gene prognostic signature.
October 31st 2017
Michelle E. Melisko, MD, discusses a variety of pivotal trials with adjuvant hormonal therapy and other developments in the treatment of patients with ER-positive breast cancer.
October 30th 2017
Howard "Skip" A. Burris, MD, discusses the ongoing research with PARP inhibitors and the advances in immunotherapy for patients with triple-negative breast cancer.